• Yuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, Richard C Becker, Robert A Harrington, Anders Himmelmann, Benjamin Neely, Steen Husted, Stefan K James, Hugo A Katus, Renato D Lopes, Ph Gabriel Steg, Robert F Storey, Lars Wallentin, Christopher P Cannon, and PLATO Investigators.
• Harvard Clinical Research Institute, Boston, MA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
• Am. Heart J. 2016 Jul 1; 177: 1-8.

BackgroundTicagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding. We evaluated whether the use of glycoprotein IIb/IIIa inhibitor (GPI) impacts the relative efficacy and safety of ticagrelor compared with clopidogrel.MethodsPLATO randomized 18,624 subjects with acute coronary syndrome to ticagrelor versus clopidogrel. The primary efficacy end point was cardiovascular death/myocardial infarction/stroke, and the primary safety end point was major bleeding. The use of GPI was at the physician's discretion and open-label. We evaluated outcomes at 30 days stratified by GPI use in the subgroup of 9,983 patients who underwent percutaneous coronary intervention (PCI) within 72 hours.ResultsA total of 4,020 (40%) received a GPI. Those receiving a GPI were more likely to be younger, be male, and undergo multivessel PCI. There was no interaction between treatment and GPI use for the primary efficacy and safety end points. Patients treated without GPI had a lower rate of definite stent thrombosis and higher rate of minor/major bleeding with ticagrelor compared with clopidogrel (P < .05), whereas there was no such difference with GPI (P interaction < .05).ConclusionsIn patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.Copyright © 2016 Elsevier Inc. All rights reserved.

46 keywords...

hide…